• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Study Says Second Opinions Matter in Breast Cancer Pathology

Article

The Roswell Park pathology team reviewed 500 breast core biopsy cases provided by referring institutions in a single calendar year and found that 8% of the cases had a major discordance and 13% had a minor discordance, especially with respect to interpreting biomarkers that determine prognosis and therapeutic options.

The review of pathology reports for breast cancer can have a significant impact on patient care, making a change in 20% of the cases examined, according to study results from Roswell Park Cancer Institute (RPCI). The study, authored by Thaer Khoury, MD, and Yousef Soofi, MD, of the Department of Pathology at RPCI, was recently published in The Breast Journal.

“Surgical pathology is a dynamically changing specialty with frequently updated guidelines and classifications,” says Dr. Khoury. “This study underscores the need for a second review of the original pathologic material by a pathologist who specializes in breast cancer prior to implementation of breast cancer therapy.”

Read the news release by Roswell Park Cancer Institute: http://bit.ly/1KS8XBN

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Jonathan E. Levitt, Esq, Frier Levitt, LLC
Judy Alberto, MHA, RPh, BCOP, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Emily Touloukian, DO, Coastal Cancer Center
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.